Hippocratic AI
AI nurse agents deployed at 50+ health systems — 115M patient interactions, zero safety incidents.
hippocraticai.com ↗Hippocratic is the healthcare AI company that's converted 'agents in regulated industries' from an open question into a measurable operational reality. 115 million patient interactions is not a demo metric — it's the kind of deployment volume that lets regulators, payors, and health-system boards benchmark safety and outcomes. Munjal Shah built this by doing the unglamorous work of validating agents against nursing guidelines, embedding in clinical workflows, and structuring the cap table so that customers are also aligned investors. For any vertical-AI founder, the Hippocratic playbook is the benchmark for how to deploy AI in regulated environments.
What's going for them.
- 01115 million+ clinical patient interactions completed with zero safety incidents — a deployment scale and safety track record that no other healthcare-AI agent product has approached.
- 0250+ large health systems, payors, and pharma clients in 6 countries — breadth of deployment that validates the product across US commercial healthcare, Medicare-era providers, and international health systems.
- 03Cap table uniquely includes health systems themselves (UHS, Memorial Hermann, WellSpan, Cincinnati Children's) as equity investors — a structural alignment that translates into deeper deployment and faster iteration than pure-VC backed competitors.
- 04Founding thesis — AI agents can address the nurse/clinician shortage without compromising safety — is now validated at a scale where industry regulators and payors are paying attention. First-mover position in a category the FDA has not yet fully frameworked.
- 05Over 1,000 clinical use cases built in the first 15 months since commercialization — the breadth of workflows (pre-op, post-discharge, chronic care management, medication adherence) makes Hippocratic the default platform for any health system serious about AI deployment.
What they built
Hippocratic AI builds AI agents for healthcare — specifically, agents that perform nurse-adjacent patient interaction work: pre-operative preparation calls, post-discharge follow-ups, chronic disease management check-ins, medication adherence support, and clinical triage escalation. The product is not a chatbot; it’s a voice-native agent platform deployed inside health-system clinical workflows with full audit trails, real-time escalation to human nurses when necessary, and safety guardrails validated against established nursing guidelines. The commercial model is outcome-based, priced by successful patient engagement rather than per-seat.
How they got here
Munjal Shah (serial healthcare entrepreneur, founder of Like.com and Health IQ) and Subhabrata Mukherjee (ex-Microsoft Research, NLP researcher) founded Hippocratic in 2023 with an explicit bet that healthcare was the biggest vertical AI opportunity and the hardest one to execute. The first 18 months were spent on safety infrastructure: training models against nursing standards, building escalation systems, and partnering with health systems (not just as customers but as investors).
The Series A in March 2024 at $500M was followed by a $141M Series B in early 2025 at $1.64B, then the November 2025 Series C at $3.5B. Through 2024 and 2025, Hippocratic went live with 50+ health systems, crossed 115 million patient interactions, and — critically — maintained zero reported safety incidents. The latter number is the metric that matters most for regulator and payor comfort; it’s also the metric that forces competitors to either match Hippocratic’s safety architecture or accept lower-risk use cases.
What’s ahead
Three things will determine Hippocratic’s trajectory. First, FDA framework: healthcare AI regulatory frameworks are crystallizing in 2026, and Hippocratic’s scale advantage gives it strong influence on how those rules get written. Second, international expansion: the UK NHS, Canadian provincial health systems, and European national health services are all evaluating AI-agent deployment, and Hippocratic is the only company with the track record to credibly bid for those contracts. Third, payor expansion: the shift from provider-led deployments (current) to payor-led deployments (where the insurer pays for patient engagement) is the single biggest revenue unlock, because payors have incentive structures that directly reward the cost savings AI agents produce.
Why it matters
Hippocratic is the most important vertical AI company in healthcare — the one that’s proving AI agents can be deployed at population scale without the patient-harm incidents that critics predicted. For vertical-AI founders, the Hippocratic approach (safety infrastructure first, customer-aligned cap table, outcome-based pricing) is the playbook for entering regulated industries. For investors, Hippocratic is the clearest exposure to the “AI eats healthcare labor shortages” thesis at institutional scale.
Founder interview coming soon.
We'll be sitting down with the founders and operators of the companies we profile — on fundraising, product decisions, and what they're building next. If you're part of the Hippocratic AI team and want to share a perspective, get in touch.
Thinking about fundraising or M&A?
Amafi Advisory works with AI companies on strategic, fundraising, M&A, and technical advisory. Even if you're just exploring.